Key result
Bufalin preserves LVEF at ~63% versus ~38% after myocardial ischemia-reperfusion injury in mice.
Why the study?
Bufalin exerts positive effects on hearts under pathological conditions, but its specific effects and mechanisms on myocardial ischemia/reperfusion injury remained to be investigated.
Does bufalin improve myocardial ischemia/reperfusion injury in male C57BL/6 J mice?
Does bufalin improve myocardial ischemia/reperfusion injury in male C57BL/6 J mice?
Bufalin ameliorates myocardial ischemia/reperfusion injury and improves cardiac function in mice by suppressing macrophage pyroptosis via the P62 pathway.
Answers are grounded in this paper and cite their sources.
Does not support clinical use of bufalin post-MI; hypothesis-generating in animal models and requires human trials.
Bufalin, which is isolated from toad venom, exerts positive effects on hearts under pathological circumstance. We aimed to investigate the effects and mechanisms of bufalin on myocardial I/R injury. In vivo, bufalin ameliorated myocardial I/R injury, which characteristics with better ejection function, decreased infarct size and less apoptosis. The levels of pyroptotic proteins were increased in I/R-treated macrophages and inflammatory cytokines expressed more in I/R-induced mouse, which could be attenuated by bufalin. Bufalin also reduced H/R-treated macrophage pyroptosis in vitro. Autophagic flux blockage and ROS accumulation were reduced by bufalin in impaired macrophages. Overexpression of p62 abrogated the anti-proptosis and anti-oxidative effects of bufalin. The levels of apoptosis related proteins were changed and TUNEL-positive ratio was raised in cardiomyocytes that received conditioned medium treatment with H/R-treated macrophages, while bufalin pretreatment could reduce apoptosis. These findings indicate that bufalin may attenuate myocardial I/R injury by suppressing macrophage pyroptosis via P62 pathway.
No takes yet. Share an insight, caveat, or question.
Li et al. (2024) studied Myocardial ischemia/reperfusion injury. Bufalin vs. PBS/Control was evaluated on Left ventricular ejection fraction (LVEF) (p=<0.05). Bufalin improved left ventricular ejection fraction and reduced infarct size in mice subjected to myocardial ischemia/reperfusion injury.
Synapse has enriched 10 related papers. Consider them for comparative context: